#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2990	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2516	353.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1831	1831	T	451	T	393	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2990	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2516	353.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1565	1565	C	407	C	335	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4896	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3935	372.7	0	.	n	.	0	T695C	SNP	695	695	T	1188	1188	C	364	C	292	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4896	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3935	372.7	0	.	n	.	0	G1365A	SNP	1365	1365	G	1858	1858	A	398	A,C	326,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4896	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3935	372.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2464	2464	C	466	C	385	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4896	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3935	372.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2538	2538	A	490	A	395	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4896	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3935	372.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3090	3090	C	436	C,A	352,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	398	folP	855	855	100.0	folP.l15.c4.ctg.1	1805	65.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1142	1144	AGC	98;98;98	A;G;C	75;79;78	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	998	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3693	80.9	1	SNP	p	S91F	0	.	.	271	273	TCC	715	717	TCC	63;63;63	T,C;C;C	47,1;47;49	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	998	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3693	80.9	1	SNP	p	D95N	0	.	.	283	285	GAC	727	729	GAC	61;61;61	G;A;C	47;45;46	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	998	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3693	80.9	1	SNP	p	D95G	0	.	.	283	285	GAC	727	729	GAC	61;61;61	G;A;C	47;45;46	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	414	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1704	72.8	1	SNP	p	G45D	1	.	.	133	135	GAC	643	645	GAC	125;126;126	G;A,G;C	98;96,1;98	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	262	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1410	55.7	0	.	n	.	0	A197.	DEL	197	197	A	787	787	A	103	A	89	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3431	79.7	1	SNP	p	D86N	0	.	.	256	258	GAC	849	851	GAC	97;96;95	G;A;C	75;70;74	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3431	79.7	1	SNP	p	S87I	0	.	.	259	261	AGT	852	854	AGT	95;95;94	A;G;T	66;75;72	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3431	79.7	1	SNP	p	S87R	0	.	.	259	261	AGT	852	854	AGT	95;95;94	A;G;T	66;75;72	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3431	79.7	1	SNP	p	S87W	0	.	.	259	261	AGT	852	854	AGT	95;95;94	A;G;T	66;75;72	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3431	79.7	1	SNP	p	S88P	0	.	.	262	264	TCC	855	857	TCC	92;91;92	T;C;C	69;73;69	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	816	parE	1986	1986	100.0	parE.l6.c17.ctg.1	2921	83.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1680	1682	GGC	105;104;104	G;G;C	83;84;85	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1490	1492	GCA	116;115;115	G;C;A	94;93;92	penA.46.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1493	1495	ATC	115;116;116	A;T;C	94;92;92	penA.46.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1505	1507	GTG	110;109;109	G,T;T;G	90,1;84;86	penA.46.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1505	1507	GTG	110;109;109	G,T;T;G	90,1;84;86	penA.46.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2009	2011	ACC	67;68;68	A;C;C	57;62;62	penA.46.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2063	2065	GCG	68;68;68	G;C,G;G	58;49,1;51	penA.46.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2063	2065	GCG	68;68;68	G;C,G;G	58;49,1;51	penA.46.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2186	2188	GGC	85;85;85	G;G;C,A	62;64;62,1	penA.46.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2195	2197	GGC	87;87;87	G,C;G;C,T,A	64,1;65;62,1,1	penA.46.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.46.001	penA.46.001	1	1	27	744	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2806	79.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2213	2215	CCG	93;95;95	C;C;G	70;72;71	penA.46.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1066	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3526	90.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1785	1787	CCG	84;84;83	C;C;G	59;59;60	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	502	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2024	74.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	650	650	C	78	C	63	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	667	669	AAG	132;131;131	A,C;A,G;G,C	112,1;106,1;109,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	E212D	NONSYN	634	636	GAA	943	945	GAT	135;134;134	G;A,C;T	111;108,1;106	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	H213G	NONSYN	637	639	CAT	946	948	GGT	136;136;136	G;G;T,C,G	111;108;107,1,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	V215A	NONSYN	643	645	GTT	952	954	GCT	136;134;134	G;C;T	109;109;107	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	I218M	NONSYN	652	654	ATC	961	963	ATG	140;140;139	A;T;G	114;113;114	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1078	1080	ACG	117;118;119	A;C;G	100;100;100	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1084	1086	GTT	117;119;119	G;T;T	100;99;98	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1198	1200	AAC	126;126;127	A;A;C	101;100;103	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	0	.	p	.	0	D333N	NONSYN	997	999	GAC	1306	1308	AAC	115;115;116	A;A;C	98;98;101	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	1	SNP	p	A121D	1	.	.	361	363	GAC	670	672	GAC	131;131;131	G;A;C	109;104;106	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	646	porB1b	1047	1047	98.66	porB1b.l15.c30.ctg.1	1556	115.5	1	SNP	p	D121N	0	.	.	361	363	GAC	670	672	GAC	131;131;131	G;A;C	109;104;106	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2000	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5194	115.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2156	2158	CAT	94;94;94	C;A;T,G	78;75;73,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	352	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1356	77.7	1	SNP	p	V57M	1	.	.	169	171	ATG	696	698	ATG	140;140;140	A;T;G	110;113;114	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
